AA amyloidosis in inflammatory joint diseases: A systematic review
Study context
- Population
- Histologically proven AA amyloidosis (AAA) in inflammatory joint disease (IJD); MEDLINE, EMBASE and Cochrane searched until October 202433 studies
- Outcome
- Incidence, prevalence, mortality and response to treatment of IJD-related AAA
Methodological detailscohorts and case series (≥ 10 patients), histologically proven AAA
- Cohorts and case series (≥ 10 patients)
- Histologically proven AAA
Pooled result
As reported in the abstract
IJD-related AAA incidence, prevalence and mortality
AAA prevalence in RA before 2010
16.7 % to 25.2 %
AAA prevalence in RA after 2010
0.7 %
AAA prevalence in AS before 2010
6.1 % to 8.5 %
AAA prevalence in AS after 2010
1.1 % to 1.3 %
Further pooled results
Response to treatment (AAA biomarkers: GFR, serum amyloid A)
- Immunomodulating therapies (especially biologics) seemed to improve AAA biomarkers, such as glomerular filtration rate and serum amyloid A level
Original publication
AA amyloidosis in inflammatory joint diseases: A systematic review. Semin Arthritis Rheum. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →